A Phase 3 interventional study of AR1001 and Placebo in Alzheimer Disease, sponsored by AriBio Co., Ltd.. Active, not recruiting at 198 sites in 13 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by AriBio Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 54th largest by enrollment of the 1,610 interventional ones that give a count, is one of 131 that started in 2022, is one of 188 in phase 3, reaches primary completion later than 57 of the 443 other live ones, and was the 1,500th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,941 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 131 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,535 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,610 interventional studies, 160 across the 309 observational. Of the 1,379 that completed or were terminated, 592 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,941 have an industry lead sponsor. The 10 most frequent:
AriBio Co., Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.
AriBio Co., Ltd. has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
164 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 164 to your calendar (.ics) → With an account.
Among the 1,941 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
The purpose of this Study is to evaluate the efficacy and safety of AR1001 in participants with Early Alzheimer's Disease (AD).
AR1001 is a small molecule that has demonstrated its potential as a therapeutic agent for AD via its polypharmacological characteristics with multiple mechanisms to ameliorate AD pathology.
The criteria were revised on the registry on Oct 14, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Positive biomarker for brain amyloid pathology as indicated by assessment of at least one of the following:
Exclusion Criteria:
Participants with any of the following:
Participants who have history of cancer or malignant tumor within 5 years prior to screening with the exception of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active, AR1001 30 mg QD will be administered daily for 52 weeks during the Treatment Phase of the study. In the Extension Phase, all eligible participants who choose to participate will receive AR1001 30 mg QD for 52 weeks.
Drug: AR1001
Placebo QD will be administered daily for 52 weeks during the Treatment Phase of the study. In the Extension Phase, all eligible participants who choose to participate will receive AR1001 30 mg QD for 52 weeks.
Drug: Placebo
AR1001 Active Oral Tablet
Placebo Oral Tablet
Change from Baseline in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) (Overall Population)
CDR-SB is used to assess clinical decline associated with AD. The CDR is a 5-point scale used to stage AD by characterization of the 6 domains of cognitive and functional performance: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. This information is collected through a semi structured interview of the participant and the informant. Scores range from 0 to 3 (0, 0.5, 1, 2, 3), with a higher score indicating greater impairment. The CDR-SB score is obtained by summing each of the CDR domain box scores, with scores ranging from 0 to 18.
Time frame: Baseline to Week 52
Change from Baseline in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) (Monotherapy Population)
CDR-SB is used to assess clinical decline associated with AD. The CDR is a 5-point scale used to stage AD by characterization of the 6 domains of cognitive and functional performance: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. This information is collected through a semi structured interview of the participant and the informant. Scores range from 0 to 3 (0, 0.5, 1, 2, 3), with a higher score indicating greater impairment. The CDR-SB score is obtained by summing each of the CDR domain box scores, with scores ranging from 0 to 18. The monotherapy population is a subset of the overall population that is not taking concomitant medication for AD during the trial.
Time frame: Baseline to Week 52
Change from Baseline in the Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog 13) (Overall Population)
ADAS-Cog13 is a clinician-administered assessment of cognitive function in individuals with Alzheimer's disease that evaluates domains including memory, language, praxis, orientation, attention, and concentration. Total scores range from 0 to 85, with higher scores indicating greater cognitive impairment.
Time frame: Baseline to Week 52
Change from Baseline in the Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog 13) (Monotherapy Population)
ADAS-Cog13 is a clinician-administered assessment of cognitive function in individuals with Alzheimer's disease that evaluates domains including memory, language, praxis, orientation, attention, and concentration. Total scores range from 0 to 85, with higher scores indicating greater cognitive impairment. The monotherapy population is a subset of the overall population that is not taking concomitant AD medication.
Time frame: Baseline to Week 52
Change from Baseline in the Amsterdam-Instrumental Activities of Daily Living Questionnaire-Short Version (A-IADL-Q-SV) (Overall Population)
The A-IADL-Q is an adaptive and computerized questionnaire designed to assess impairments in instrumental activities of daily living (IADL) in early dementia. The questionnaire is completed by a caregiver. Higher scores indicate better everyday functioning
Time frame: Baseline to Week 52
Change from Baseline in the Amsterdam-Instrumental Activities of Daily Living Questionnaire-Short Version (A-IADL-Q-SV) (Monotherapy Population)
The A-IADL-Q is an adaptive and computerized questionnaire designed to assess impairments in instrumental activities of daily living (IADL) in early dementia. The questionnaire is completed by a caregiver. Higher scores indicate better everyday functioning. The monotherapy population is a subset of the overall population that is not taking concomitant medication for AD during the trial.
Time frame: Baseline to Week 52
Change from Baseline in the Geriatric Depression Scale-15 (GDS-15) (Overall Population)
The GDS-15 assesses depressive symptoms using 15 items. Scores range from 0 to 15, with higher scores indicating more depressive symptoms.
Time frame: Baseline to Week 52
Change from Baseline in the Geriatric Depression Scale-15 (GDS-15) (Monotherapy Population)
The GDS-15 is a validated 15-item self-report questionnaire used to screen for depressive symptoms in older adults. Total scores range from 0 to 15, with higher scores indicating greater depressive symptom severity. The monotherapy population is a subset of the overall population that is not taking concomitant medication for AD during the trial.
Time frame: Baseline to Week 52
Change from Baseline in the Mini-Mental Status Examination (MMSE) (Overall Population)
The MMSE is a clinician-administered assessment of global cognitive function that evaluates orientation, attention, memory, language, and visuospatial abilities. Total scores range from 0 to 30, with lower scores indicating greater cognitive impairment.
Time frame: Baseline to Week 52
Change from Baseline in the Mini-Mental Status Examination (MMSE) (Monotherapy Population)
The MMSE is a clinician-administered assessment of global cognitive function that evaluates orientation, attention, memory, language, and visuospatial abilities. Total scores range from 0 to 30, with lower scores indicating greater cognitive impairment. The monotherapy population is a subset of the overall population that is not taking concomitant medication for AD during the trial.
Time frame: Baseline to Week 52
Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
Number of participants experiencing at least one treatment-emergent adverse event (TEAE) during the safety assessment period. A TEAE is defined as an adverse event that first occurs or worsens in severity after initiation of study treatment, in accordance with the protocol-defined treatment-emergent period.
Time frame: Up to 108 weeks
Number of Participants With at Least One Treatment-Emergent Serious Adverse Event (TESAE)
Number of participants experiencing at least one treatment-emergent serious adverse event (TESAE) during the safety assessment period. A TESAE is a serious adverse event that first occurs or worsens after initiation of study treatment, in accordance with the protocol-defined treatment-emergent period. Seriousness is determined using the criteria specified in the study protocol.
Time frame: Up to 108 weeks
Changes From Baseline in Vital Signs and Incidence of Potentially Clinically Significant Vital Sign Abnormalities
Changes from baseline in systolic and diastolic blood pressure, pulse rate, body temperature, respiratory rate, and weight will be summarized by visit. The number and percentage of participants with potentially clinically significant treatment-emergent vital sign abnormalities will also be summarized using predefined criteria.
Time frame: Up to 108 weeks
Changes From Baseline in Electrocardiogram (ECG) Parameters and Incidence of Abnormal ECG Findings
Changes from baseline in 12-lead ECG parameters, including heart rate, PR interval, QRS duration, QT interval, RR interval, and Fridericia-corrected QT interval (QTcF), will be summarized. The number and percentage of participants with abnormal post-baseline ECG findings, classified as clinically significant or not clinically significant, will also be summarized.
Time frame: Up to 108 Weeks
Changes From Baseline in Clinical Laboratory Parameters and Laboratory Abnormalities
Changes from baseline in hematology, serum chemistry, coagulation, and urinalysis parameters will be summarized by visit. Laboratory abnormalities will be evaluated using laboratory reference ranges, and shifts from baseline to the maximum post-baseline Common Terminology Criteria for Adverse Events (CTCAE) grade will be summarized for hematology and chemistry parameters.
Time frame: Up to 108 weeks
Number of Participants With Suicidal Ideation, Suicidal Behavior, or Non-Suicidal Self-Injurious Behavior Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)
The Columbia-Suicide Severity Rating Scale (C-SSRS) assesses suicidal ideation, suicidal behavior, and non-suicidal self-injurious behavior. The number and percentage of participants reporting suicidal ideation, suicidal behavior, suicidal ideation or behavior, and non-suicidal self-injurious behavior will be summarized by visit and overall. Changes in categorical responses from baseline will also be summarized for suicidal ideation and behavior. The most severe response during treatment will be used for the overall assessment.
Time frame: Up to 108 weeks
Quality of Life in Alzheimer's Disease (QoL-AD), Participant Version
The Quality of Life in Alzheimer's Disease (QoL-AD) questionnaire assesses quality of life across 13 domains, including physical health, mood, relationships, activities, and ability to complete tasks. The participant version is completed by the study participant. Total scores range from 13 to 52, with higher scores indicating better quality of life. Change from baseline will be assessed at Weeks 52 and 104.
Time frame: Baseline to Weeks 52 and 104
Quality of Life in Alzheimer's Disease (QoL-AD), Informant Version
The Quality of Life in Alzheimer's Disease (QoL-AD) informant questionnaire assesses the participant's quality of life across 13 domains, including physical health, mood, relationships, activities, and ability to complete tasks, as reported by an informant. Total scores range from 13 to 52, with higher scores indicating better quality of life. Change from baseline will be assessed at Weeks 52 and 104.
Time frame: Baseline to Weeks 52 and 104
Change From Baseline to Week 52 in Global Statistical Test (GST) Score
The Global Statistical Test (GST) combines the Clinical Dementia Rating-Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13), Amsterdam-Instrumental Activities of Daily Living Questionnaire Short Version (A-IADL-Q-SV), Geriatric Depression Scale-15 (GDS-15), and Mini-Mental State Examination (MMSE) using a rank-sum percentile method. The composite score is normalized to a scale of 0 to 100, with higher scores indicating worse overall clinical status.
Time frame: Baseline to Week 52
Change From Baseline and Week 52 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) through Week 104
The CDR-SB evaluates cognitive and functional impairment across six domains. Total scores range from 0 to 18, with higher scores indicating greater impairment. Changes from baseline and from Week 52 will be evaluated during the optional open-label Extension Phase. Participants will be analyzed by original randomized treatment group (early-start AR1001 versus delayed-start AR1001).
Time frame: Baseline and Week 52 to Week 104
Change From Baseline and Week 52 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) through Week 104
The ADAS-Cog13 assesses cognitive performance. Total scores range from 0 to 85, with higher scores indicating greater impairment. Changes from baseline and from Week 52 will be evaluated during the optional open-label Extension Phase. Participants will be analyzed by original randomized treatment group (early-start AR1001 versus delayed-start AR1001).
Time frame: Baseline and Week 52 to Week 104
Change From Baseline and Week 52 in Amsterdam-Instrumental Activities of Daily Living Questionnaire Short Version (A-IADL-Q-SV) through Week 104
The A-IADL-Q-SV assesses impairment in instrumental activities of daily living. Scores range from 0 to 100, with higher scores indicating worse functioning. Changes from baseline and from Week 52 will be evaluated during the optional open-label Extension Phase. Participants will be analyzed by original randomized treatment group (early-start AR1001 versus delayed-start AR1001).
Time frame: Baseline and Week 52 to Week 104
Change From Baseline and Week 52 in Geriatric Depression Scale-15 (GDS-15) through Week 104
The GDS-15 assesses depressive symptoms using 15 items. Scores range from 0 to 15, with higher scores indicating more depressive symptoms. Changes from baseline and from Week 52 will be evaluated during the optional open-label Extension Phase. Participants will be analyzed by original randomized treatment group (early-start AR1001 versus delayed-start AR1001).
Time frame: Baseline and Week 52 to Week 104
Change From Baseline and Week 52 in Mini-Mental State Examination (MMSE) Through Week 104
The MMSE assesses global cognitive function. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. Changes from baseline and from Week 52 will be evaluated during the optional open-label Extension Phase. Participants will be analyzed by original randomized treatment group (early-start AR1001 versus delayed-start AR1001).
Time frame: Baseline and Week 52 to Week 104
Change From Baseline in Plasma phosphorylated Tau at Threonine 217 (pTau217)
Plasma pTau217 is a biomarker associated with Alzheimer's disease-related tau pathology. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.
Time frame: Baseline to Weeks 52 and 104
Change From Baseline in Plasma Glial Fibrillary Acidic Protein (GFAP)
Plasma GFAP is a biomarker associated with astrocytic activation. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.
Time frame: Baseline to Weeks 52 and 104
Change From Baseline in Plasma Neurofilament Light Chain (NfL)
Plasma NfL is a biomarker associated with neuroaxonal injury. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.
Time frame: Baseline to Weeks 52 and 104
Change From Baseline in Plasma Amyloid Beta 42 (Aβ42)
Plasma Aβ42 is an amyloid-related biomarker. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.
Time frame: Baseline to Weeks 52 and 104
Change From Baseline in Plasma Amyloid Beta 40 (Aβ40)
Plasma Aβ40 is an amyloid-related biomarker. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.
Time frame: Baseline to Weeks 52 and 104
Change From Baseline in Plasma amyloid beta 42 to amyloid beta 40 ratio (Aβ42/Aβ40)
The plasma Aβ42/Aβ40 ratio is an amyloid-related biomarker calculated from the measured concentrations of Aβ42 and Aβ40. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.
Time frame: Baseline to Weeks 52 and 104
Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Cyclic Guanosine Monophosphate (cGMP)
cGMP a signaling molecule associated with the nitric oxide/cGMP pathway. Change from baseline to Week 52 in CSF cGMP will be evaluated to assess the effect of AR1001 compared with placebo.
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Cyclic Adenosine Monophosphate (cAMP)
cAMP is an intracellular signaling molecule. Change from baseline to Week 52 in CSF cAMP will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) phosphorylated Tau at Threonine 217 (pTau217)
pTau217 is a biomarker associated with Alzheimer's disease-related tau pathology. Change from baseline to Week 52 in CSF pTau217 will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Glial Fibrillary Acidic Protein (GFAP)
GFAP is a biomarker associated with astrocytic activation. Change from baseline to Week 52 in CSF GFAP will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Amyloid Beta 42 (Aβ42)
Aβ42 is an amyloid-related biomarker. Change from baseline to Week 52 in CSF Aβ42 will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Amyloid Beta 40 (Aβ40)
Aβ40 is an amyloid-related biomarker. Change from baseline to Week 52 in CSF Aβ40 will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Amyloid Beta 42 to Amyloid Beta 40 ratio (Aβ42/Aβ40)
Aβ42/Aβ40 ratio is an amyloid-related biomarker calculated from measured CSF Aβ42 and Aβ40 concentrations. Change from baseline to Week 52 in CSF Aβ42/Aβ40 will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Volumetric MRI
Change from baseline to Week 52 in whole brain volume and brain region (i.e, hippocamus) volumes will be assessed using volumetric magnetic resonance imaging (MRI).
Time frame: Baseline to Week 52
Plasma Concentrations of AR1001 for Population Pharmacokinetic Analysis
Plasma concentrations of AR1001 will be measured to characterize the single-dose and multiple-dose population pharmacokinetic profile. Samples will be collected pre-dose and at 30, 60, and 120 minutes postdose at Weeks 0, 26, and 52.
Time frame: Weeks 0, 26, and 52
Plasma Concentrations of M14 for Population Pharmacokinetic Analysis
Plasma concentrations of M14 will be measured to characterize the single-dose and multiple-dose population pharmacokinetic profile. Samples will be collected pre-dose and at 30, 60, and 120 minutes postdose at Weeks 0, 26, and 52.
Time frame: Weeks 0, 26, and 52
Showing the first 100 of 198 sites across 13 countries. Choose a country and city above to see the rest.
Ran from Dec 2022 to primary completion in Jun 2026, 42 months.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 42 months is close to that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion May 2026 → Jun 2026 and completion Dec 2027 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AriBio Co., Ltd.